Efficacy

ESPS 2: Effects on Stroke - Relative Risk Reduction (Pairwise Comparisons)

Extended-release dipyridamole (ER-DP) and ASA have an additive effect on the prevention of stroke, as indicated by results from pairwise comparisons of relative risk reduction.
Treatment with ASA alone and with ER-DP alone lead to a similar risk reduction of 18.1% and 16.3%, respectively. Combination therapy with ER-DP + ASA showed significantly better stroke prevention vs. placebo (37.0%) as well as vs. ASA alone (23.1%).
Additionally, the statistically significant effect of ER-DP alone is a new element in the field of secondary prevention of stroke, since ER-DP 400 mg daily is shown here to be as effective as ASA when given alone.